Previous close | 19.80 |
Open | 17.78 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 17.78 - 18.42 |
52-week range | 17.78 - 19.80 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company websiteBondholder meeting now planned for early May as the company continues to engage with bondholders Allschwil, Switzerland – April 17, 2024Idorsia Ltd (SIX: IDIA) today announced that its Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting is available on the company website at the follow
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of IdorsiaMain investors Jean-Paul and Martine Clozel fully support this requestFinancial status as of March 31, 2024, to be published on April 17, 2024, in conjunction with the invitation to the bondholder meetingPostponement of the Full Year 2023 and Q1 2024 Financial Results publication to May 21, 2
Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024 Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor, especia